Breaking News Instant updates and real-time market news.

ALT

Altimmune

$15.16 /

+0.15 (+1.00%)

07:07
09/28/21
09/28
07:07
09/28/21
07:07

Altimmune announces results from 12-week Phase 1 trial of ALT-801

Altimmune announced positive results from a 12-week, Phase 1 trial of pemvidutide, an investigational glucagon-like peptide-1/glucagon dual receptor agonist. The Phase 1 study was a first-in-human, randomized, placebo-controlled, single ascending dose and multiple ascending dose study in overweight and obese volunteers performed in Australia under a clinical trial application. Eligible participants included healthy, non-diabetic subjects with a minimum body mass index of 25 kg/m2. Thirty-four subjects in the MAD portion of the study were assigned to receive one of three subcutaneous doses of pemvidutide or placebo once weekly for 12 weeks without dose titration. Behavioral and caloric restrictive interventions were not employed. At 12 weeks, subjects receiving pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.6%. Weight loss occurred rapidly and consistently over 12-weeks. Side effects were mild to moderate, with no serious or severe treatment-emergent adverse events. Importantly, no discontinuations due to adverse events were reported The 1.8 mg dose cohort experienced the highest weight loss, with 100% of subjects losing at least 5% of body weight and 55% of subjects losing at least 10% of their body weight. The amounts of weight loss at the 1.8 and 2.4 mg doses were essentially the same given the sample size and overlapping confidence intervals. No correlation was found between the magnitude of weight loss and either age or baseline BMI. Favorable trends were observed in secondary measures, including reductions in systolic and diastolic blood pressure, serum lipids, and HOMA-IR. In addition, a rise in ketone bodies was observed, consistent with the effects of glucagon on fat metabolism. Even without dose titration, the symptoms experienced by subjects who received pemvidutide 1.8 mg were predominantly mild, did not need treatment and were consistent with known effects of GLP-1 therapies. Further, tolerability decreased with higher dose levels. There were no hyperglycemia adverse events and no increases in the mean heart rate were observed at 6 and 12 weeks of therapy. One patient experienced elevated ALT levels that resolved rapidly after a pause in dosing. An Investigational New Drug application in non-alcoholic steatohepatitis has cleared the U.S. Food and Drug Administration review and will enable additional clinical studies beyond the current Phase 1 trial, including a 12-week trial to measure reduction in liver fat content in diabetic and non-diabetic subjects with non-alcoholic fatty liver disease, which is expected to commence in the near future. The Company has commenced a drug-drug interaction trial and also plans to conduct a trial of glucose control in patients with type 2 diabetes that is anticipated to start in the fourth quarter of this year. Altimmune also intends to begin a 52-week Phase 2 biopsy-driven NASH trial in H1 2022. The Company intends to file a second IND application in obesity in Q4 2021 with plans to initiate a 48-week, Phase 2 obesity trial in H1 2022.

ALT Altimmune
$15.16 /

+0.15 (+1.00%)

09/08/21 Piper Sandler
Altimmune price target raised to $34 from $16 at Piper Sandler
09/07/21 B. Riley
Altimmune price target raised to $27 from $21 at B. Riley
08/20/21 JMP Securities
Altimmune's ALT-801 data 'impressive', says JMP Securities
08/12/21 Jefferies
Altimmune price target raised to $30 from $14 at Jefferies

TODAY'S FREE FLY STORIES

Options
IronNet call volume above normal and directionally bullish » 10:25
12/07/21
12/07
10:25
12/07/21
10:25
IRNT

IronNet

$7.92 /

+0.63 (+8.64%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IRNT IronNet
$7.92 /

+0.63 (+8.64%)

IRNT IronNet
$7.92 /

+0.63 (+8.64%)

11/29/21 Jefferies
IronNet price target lowered to $10 from $27 at Jefferies
09/29/21
Fly Intel: Top five analyst initiations
09/29/21 Jefferies
IronNet initiated with a Hold at Jefferies
09/27/21 Needham
IronNet initiated with a Buy at Needham
IRNT IronNet
$7.92 /

+0.63 (+8.64%)

IRNT IronNet
$7.92 /

+0.63 (+8.64%)

Conference/Events
Morgan Stanley municipal strategist to hold analyst/industry conference call » 10:25
12/07/21
12/07
10:25
12/07/21
10:25

US Chief Municipal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
A-Mark Precious Metals to host conference call » 10:25
12/07/21
12/07
10:25
12/07/21
10:25
AMRK

A-Mark Precious Metals

$64.02 /

+2.02 (+3.26%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMRK A-Mark Precious Metals
$64.02 /

+2.02 (+3.26%)

AMRK A-Mark Precious Metals
$64.02 /

+2.02 (+3.26%)

11/05/21 Roth Capital
A-Mark Precious Metals price target raised to $90 from $72 at Roth Capital
09/30/21 Roth Capital
A-Mark Precious Metals price target raised to $72 from $60 at Roth Capital
09/15/21 DA Davidson
A-Mark Precious Metals price target raised to $71 from $66 at DA Davidson
03/19/21 DA Davidson
A-Mark Precious Metals initiated with a Buy at DA Davidson
AMRK A-Mark Precious Metals
$64.02 /

+2.02 (+3.26%)

  • 04
    Mar
AMRK A-Mark Precious Metals
$64.02 /

+2.02 (+3.26%)

AMRK A-Mark Precious Metals
$64.02 /

+2.02 (+3.26%)

Conference/Events
Ericsson to host business news update conference call » 10:25
12/07/21
12/07
10:25
12/07/21
10:25
ERIC

Ericsson

$10.36 /

+0.025 (+0.24%)

Management holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

11/30/21 Citi
Vonage downgraded to Neutral from Buy at Citi
11/23/21 Gordon Haskett
Gordon Haskett highlights Tyson, Xerox after Ericsson-Vonage deal
11/23/21 KeyBanc
Vonage downgraded to Sector Weight from Overweight at KeyBanc
10/25/21 BofA
Ericsson reinstated with an Underperform at BofA
ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

ERIC Ericsson
$10.36 /

+0.025 (+0.24%)

Hot Stocks
AstraZeneca, Daiichi Sankyo report updated data from TROPION-PanTumor01 trial » 10:24
12/07/21
12/07
10:24
12/07/21
10:24
AZN

AstraZeneca

$53.65 /

-1.76 (-3.18%)

, DSNKY

Daiichi Sankyo

$23.70 /

-1.46 (-5.80%)

New data from the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

04:41 Today Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

Hot Stocks
AeroVironment trading resumes  10:24
12/07/21
12/07
10:24
12/07/21
10:24
AVAV

AeroVironment

$78.77 /

-1.16 (-1.45%)

 
ShowHide Related Items >><<
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

Technical Analysis
DJ Utility Average: Pivot points » 10:24
12/07/21
12/07
10:24
12/07/21
10:24
$DJU

DJ Utility Average

/

+

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$DJU DJ Utility Average
/

+

Technical Analysis
NASDAQ market internals summary » 10:23
12/07/21
12/07
10:23
12/07/21
10:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Conference/Events
Pivotal Acquisition participates in a conference call with Needham » 10:23
12/07/21
12/07
10:23
12/07/21
10:23
PVT

Pivotal Acquisition

/

+

Technology Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
Hot Stocks
AeroVironment halted for volatility after dropping 20% to $63.72  10:23
12/07/21
12/07
10:23
12/07/21
10:23
AVAV

AeroVironment

$78.77 /

-1.16 (-1.45%)

 
ShowHide Related Items >><<
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

Hot Stocks
AeroVironment says remains well positioned despite 'current market headwinds' » 10:22
12/07/21
12/07
10:22
12/07/21
10:22
AVAV

AeroVironment

$78.77 /

-1.16 (-1.45%)

The company said in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

Technical Analysis
NYSE market internals summary » 10:22
12/07/21
12/07
10:22
12/07/21
10:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Hot Stocks
ViacomCBS 'frustrated' by where stock trades, has 'conviction' in path ahead » 10:22
12/07/21
12/07
10:22
12/07/21
10:22
VIAC

ViacomCBS

$32.17 /

+1.05 (+3.37%)

ViacomCBS CEO Bob Bakish…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

10/15/21 Deutsche Bank
ViacomCBS price target lowered to $44 from $45 at Deutsche Bank
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Wells Fargo
ViacomCBS upgraded to Overweight from Equal Weight at Wells Fargo
08/06/21
Fly Intel: Top five analyst upgrades
VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

VIAC ViacomCBS
$32.17 /

+1.05 (+3.37%)

Conference/Events
SABCS to hold a symposium » 10:22
12/07/21
12/07
10:22
12/07/21
10:22
AZN

AstraZeneca

$53.65 /

-1.76 (-3.18%)

, BYSI

BeyondSpring

$4.59 /

+0.5 (+12.22%)

, CHRS

Coherus Biosciences

$17.68 /

+0.06 (+0.34%)

, CNTX

Context Therapeutics

$5.63 /

+0.04 (+0.72%)

, DSNKY

Daiichi Sankyo

$23.70 /

-1.46 (-5.80%)

, ESALY

Eisai

$60.67 /

+0.47 (+0.78%)

, EXAS

Exact Sciences

$83.65 /

+2.75 (+3.40%)

, GILD

Gilead

$69.06 /

-0.44 (-0.63%)

, GH

Guardant Health

$94.94 /

+6.3 (+7.11%)

, INCY

Incyte

$66.58 /

+1.57 (+2.42%)

, JAGX

Jaguar Health

$1.23 /

+0.065 (+5.58%)

, LLY

Eli Lilly

$243.25 /

-2.945 (-1.20%)

, MGNX

MacroGenics

$17.22 /

+0.5 (+2.99%)

, MRK

Merck

$72.16 /

-1.26 (-1.72%)

, MYGN

Myriad Genetics

$26.16 /

+1.17 (+4.68%)

, NTRA

Natera

$92.20 /

+6.06 (+7.04%)

, NEO

NeoGenomics

$34.37 /

+2.78 (+8.80%)

, NVS

Novartis

$80.49 /

-0.03 (-0.04%)

, OLMA

Olema Oncology

$11.28 /

+0.78 (+7.43%)

, OCX

OncoCyte

$2.42 /

+0.11 (+4.76%)

, ONCY

Oncolytics

$1.68 /

+0.07 (+4.35%)

, PBYI

Puma Biotechnology

$3.00 /

+0.03 (+1.01%)

, PFE

Pfizer

$51.75 /

+0.25 (+0.49%)

, RHHBY

Roche

$49.73 /

+0.38 (+0.77%)

, SNY

Sanofi

$47.51 /

-0.06 (-0.13%)

, SGEN

Seagen

$148.08 /

+2.06 (+1.41%)

, SPPI

Spectrum

$1.54 /

+0.17 (+12.41%)

, VCYT

Veracyte

$40.67 /

+3.12 (+8.31%)

, VERU

Veru

$6.32 /

+0.14 (+2.27%)

, VTRS

Viatris

$12.50 /

+0.065 (+0.52%)

, ZYME

Zymeworks

$18.97 /

+0.735 (+4.03%)

San Antonio Breast Cancer…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

CHRS Coherus Biosciences
$17.68 /

+0.06 (+0.34%)

CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

VERU Veru
$6.32 /

+0.14 (+2.27%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

04:41 Today Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

12/02/21 Evercore ISI
BeyondSpring price target lowered to $25 from $95 at Evercore ISI
12/02/21 Jefferies
Jefferies cuts BeyondSpring to Hold, slashes target to $5 after plinabulin CRL
12/02/21 Jefferies
BeyondSpring downgraded to Hold from Buy at Jefferies
12/01/21 BofA
BeyondSpring downgraded to Underperform from Buy at BofA
CHRS Coherus Biosciences
$17.68 /

+0.06 (+0.34%)

11/09/21 H.C. Wainwright
Coherus Biosciences price target lowered to $30 from $36 at H.C. Wainwright
07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

DSNKY Daiichi Sankyo
$23.70 /

-1.46 (-5.80%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
ESALY Eisai
$60.67 /

+0.47 (+0.78%)

10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GILD Gilead
$69.06 /

-0.44 (-0.63%)

04:58 Today Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
GH Guardant Health
$94.94 /

+6.3 (+7.11%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
INCY Incyte
$66.58 /

+1.57 (+2.42%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

07/07/21
Fly Intel: Top five analyst initiations
07/07/21 Cantor Fitzgerald
Jaguar Health initiated with an Overweight at Cantor Fitzgerald
02/24/21 Ladenburg
Jaguar Health transferred with Buy, $3.75 target at Ladenburg
LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
MRK Merck
$72.16 /

-1.26 (-1.72%)

09:51 Today
Fly Intel: Top five analyst downgrades
07:50 Today Guggenheim
Guggenheim downgrades Merck on Keytruda concentration, low pipeline visibility
06:10 Today Guggenheim
Merck downgraded to Neutral from Buy at Guggenheim
11/29/21
Fly Intel: Top five analyst downgrades
MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
NTRA Natera
$92.20 /

+6.06 (+7.04%)

11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
10/19/21 Canaccord
Natera Prospera Lung launch to continue momentum, says Canaccord
10/14/21 Cowen
Natera coverage transferred at Cowen
08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

07:56 Today Needham
NeoGenomics price target lowered to $41 from $48 at Needham
11/05/21 Morgan Stanley
Morgan Stanley downgrades NeoGenomics, sees limited near-term upside
11/05/21 Morgan Stanley
NeoGenomics downgraded to Equal Weight from Overweight at Morgan Stanley
10/14/21 Raymond James
NeoGenomics upgraded to Outperform from Market Perform at Raymond James
NVS Novartis
$80.49 /

-0.03 (-0.04%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
12/06/21 Cowen
Olema Oncology assumed with an Outperform at Cowen
10/11/21
Olema Oncology participates in a conference call with JPMorgan
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

04/12/21 Lake Street
AACR data strengthens 'pan-cancer credentials' for OncoCyte, says Lake Street
04/12/21 Piper Sandler
OncoCyte remains a top pick small-cap pick at Piper Sandler
03/30/21 Piper Sandler
OncoCyte called 'top small-cap pick' at Piper Sandler
03/17/21
Fly Intel: Top five analyst initiations
ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

02/17/21 H.C. Wainwright
Oncolytics initiated with a Buy at H.C. Wainwright
PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Citi
Puma Biotechnology upgraded to Buy after 40% selloff at Citi
09/27/21 Citi
Puma Biotechnology upgraded to Buy from Neutral at Citi
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
PFE Pfizer
$51.75 /

+0.25 (+0.49%)

12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
RHHBY Roche
$49.73 /

+0.38 (+0.77%)

04:41 Today Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
SNY Sanofi
$47.51 /

-0.06 (-0.13%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
SGEN Seagen
$148.08 /

+2.06 (+1.41%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
06/15/21 Raymond James
Veracyte initiated with an Outperform at Raymond James
VERU Veru
$6.32 /

+0.14 (+2.27%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VTRS Viatris
$12.50 /

+0.065 (+0.52%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
10/06/21 Jefferies
Zymeworks initiated with a Hold at Jefferies
09/13/21 Raymond James
Zymeworks data continue to outperform Herceptin, says Raymond James
08/05/21 H.C. Wainwright
Zymeworks price target lowered to $44 from $55 at H.C. Wainwright
AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

OCX OncoCyte
$2.42 /

+0.11 (+4.76%)

ONCY Oncolytics
$1.68 /

+0.07 (+4.35%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

VERU Veru
$6.32 /

+0.14 (+2.27%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

  • 20
    Oct
  • 22
    Jul
  • 18
    Feb
  • 05
    Feb
  • 05
    Feb
  • 07
    Jan
AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

CNTX Context Therapeutics
$5.63 /

+0.04 (+0.72%)

ESALY Eisai
$60.67 /

+0.47 (+0.78%)

EXAS Exact Sciences
$83.65 /

+2.75 (+3.40%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

GH Guardant Health
$94.94 /

+6.3 (+7.11%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

JAGX Jaguar Health
$1.23 /

+0.065 (+5.58%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

MGNX MacroGenics
$17.22 /

+0.5 (+2.99%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

MYGN Myriad Genetics
$26.16 /

+1.17 (+4.68%)

NTRA Natera
$92.20 /

+6.06 (+7.04%)

NEO NeoGenomics
$34.37 /

+2.78 (+8.80%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

OLMA Olema Oncology
$11.28 /

+0.78 (+7.43%)

PBYI Puma Biotechnology
$3.00 /

+0.03 (+1.01%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

RHHBY Roche
$49.73 /

+0.38 (+0.77%)

SNY Sanofi
$47.51 /

-0.06 (-0.13%)

SGEN Seagen
$148.08 /

+2.06 (+1.41%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

VCYT Veracyte
$40.67 /

+3.12 (+8.31%)

ZYME Zymeworks
$18.97 /

+0.735 (+4.03%)

AZN AstraZeneca
$53.65 /

-1.76 (-3.18%)

BYSI BeyondSpring
$4.59 /

+0.5 (+12.22%)

GILD Gilead
$69.06 /

-0.44 (-0.63%)

INCY Incyte
$66.58 /

+1.57 (+2.42%)

LLY Eli Lilly
$243.25 /

-2.945 (-1.20%)

MRK Merck
$72.16 /

-1.26 (-1.72%)

NVS Novartis
$80.49 /

-0.03 (-0.04%)

PFE Pfizer
$51.75 /

+0.25 (+0.49%)

SPPI Spectrum
$1.54 /

+0.17 (+12.41%)

VTRS Viatris
$12.50 /

+0.065 (+0.52%)

Earnings
AeroVironment lowers 2022 sales outlook to $440M-$460M from $560M-$580M » 10:21
12/07/21
12/07
10:21
12/07/21
10:21
AVAV

AeroVironment

$78.77 /

-1.16 (-1.45%)

Lowers fiscal 2022 EPS…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

AVAV AeroVironment
$78.77 /

-1.16 (-1.45%)

Earnings
AeroVironment reports Q2 adjusted EPS 78c, consensus 62c » 10:19
12/07/21
12/07
10:19
12/07/21
10:19
AVAV

AeroVironment

$79.08 /

-0.85 (-1.06%)

Reports Q2 revenue $122M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVAV AeroVironment
$79.08 /

-0.85 (-1.06%)

AVAV AeroVironment
$79.08 /

-0.85 (-1.06%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$79.08 /

-0.85 (-1.06%)

AVAV AeroVironment
$79.08 /

-0.85 (-1.06%)

Hot Stocks
AeroVironment trading halted, volatility trading pause  10:18
12/07/21
12/07
10:18
12/07/21
10:18
AVAV

AeroVironment

$78.91 /

-1.025 (-1.28%)

 
ShowHide Related Items >><<
AVAV AeroVironment
$78.91 /

-1.025 (-1.28%)

AVAV AeroVironment
$78.91 /

-1.025 (-1.28%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$78.91 /

-1.025 (-1.28%)

AVAV AeroVironment
$78.91 /

-1.025 (-1.28%)

Hot Stocks
ViacomCBS CEO says subscriber growth accelerating in Q4 » 10:17
12/07/21
12/07
10:17
12/07/21
10:17
VIAC

ViacomCBS

$31.88 /

+0.76 (+2.44%)

ViacomCBS CEO Bob Bakish…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

10/15/21 Deutsche Bank
ViacomCBS price target lowered to $44 from $45 at Deutsche Bank
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Wells Fargo
ViacomCBS upgraded to Overweight from Equal Weight at Wells Fargo
08/06/21
Fly Intel: Top five analyst upgrades
VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

VIAC ViacomCBS
$31.88 /

+0.76 (+2.44%)

Hot Stocks
Twitter acquires Quill, terms not disclosed » 10:17
12/07/21
12/07
10:17
12/07/21
10:17
TWTR

Twitter

$46.01 /

+1.535 (+3.45%)

In a tweet, Nick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$46.01 /

+1.535 (+3.45%)

TWTR Twitter
$46.01 /

+1.535 (+3.45%)

12/02/21 UBS
Twitter assumed with a Neutral at UBS
12/02/21 Piper Sandler
Twitter price target lowered to $54 from $70 at Piper Sandler
12/01/21 Citi
Twitter price target lowered to $47 from $60 at Citi
11/30/21 Jefferies
Twitter leadership changes 'step in right direction,' says Jefferies
TWTR Twitter
$46.01 /

+1.535 (+3.45%)

TWTR Twitter
$46.01 /

+1.535 (+3.45%)

TWTR Twitter
$46.01 /

+1.535 (+3.45%)

TWTR Twitter
$46.01 /

+1.535 (+3.45%)

Technical Analysis
Dow Jones Industrial Average: Pivot points » 10:17
12/07/21
12/07
10:17
12/07/21
10:17
DJX

Dow Jones Industrial Average

/

+

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DJX Dow Jones Industrial Average
/

+

11/26/21 Morgan Stanley
Covid variant mutations may reduce vaccine effectiveness, says Morgan Stanley
11/26/21 Credit Suisse
Concerns over new Covid variant 'understandable,' says Credit Suisse
DJX Dow Jones Industrial Average
/

+

DJX Dow Jones Industrial Average
/

+

Hot Stocks
AeroVironment sinks 17% after reporting Q2 results, cutting outlook  10:17
12/07/21
12/07
10:17
12/07/21
10:17
AVAV

AeroVironment

$79.10 /

-0.83 (-1.04%)

 
ShowHide Related Items >><<
AVAV AeroVironment
$79.10 /

-0.83 (-1.04%)

AVAV AeroVironment
$79.10 /

-0.83 (-1.04%)

10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
10/21/21 RBC Capital
AeroVironment initiated with a Sector Perform at RBC Capital
09/09/21 Canaccord
AeroVironment results stronger than expected, says Canaccord
09/03/21 Canaccord
AeroVironment price target raised to $88 from $84 at Canaccord
AVAV AeroVironment
$79.10 /

-0.83 (-1.04%)

AVAV AeroVironment
$79.10 /

-0.83 (-1.04%)

Options
Comcast put volume heavy and directionally bearish » 10:15
12/07/21
12/07
10:15
12/07/21
10:15
CMCSA

Comcast

$52.36 /

-0.01 (-0.02%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

11/22/21 Loop Capital
Comcast price target lowered to $67 from $71 at Loop Capital
11/01/21 Citi
Comcast price target lowered to $60 from $65 at Citi
11/01/21 Barclays
Comcast price target lowered to $60 from $65 at Barclays
10/29/21 Pivotal Research
Comcast price target lowered to $72 from $75 at Pivotal Research
CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

CMCSA Comcast
$52.36 /

-0.01 (-0.02%)

Hot Stocks
Usio, Voyager Digital extend exclusive ACH payments processing relationship » 10:14
12/07/21
12/07
10:14
12/07/21
10:14
USIO

Usio

$5.87 /

+0.36 (+6.53%)

, VYGVF

Voyager Digital

$13.31 /

+0.205 (+1.56%)

Usio, Inc. (USIO)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
USIO Usio
$5.87 /

+0.36 (+6.53%)

VYGVF Voyager Digital
$13.31 /

+0.205 (+1.56%)

USIO Usio
$5.87 /

+0.36 (+6.53%)

08:07 Today Barrington
Usio selloff brings 'solid buying opportunity,' says Barrington
03/30/21 Alliance Global Partners
Usio's Q4 gross margin not sustainable, says Alliance Global Partners
02/16/21 Alliance Global Partners
Usio shares 'over-bought' after 320% rally, says Alliance Global Partners
VYGVF Voyager Digital
$13.31 /

+0.205 (+1.56%)

11/01/21 Craig-Hallum
Voyager Digital price target raised to $25 from $20 at Craig-Hallum
07/28/21 Eight Capital
Voyager Digital initiated with a Buy at Eight Capital
07/19/21 Craig-Hallum
Voyager Digital price target lowered to $28 from $35 at Craig-Hallum
07/08/21 BTIG
Voyager Digital initiated with a Buy at BTIG
USIO Usio
$5.87 /

+0.36 (+6.53%)

VYGVF Voyager Digital
$13.31 /

+0.205 (+1.56%)

USIO Usio
$5.87 /

+0.36 (+6.53%)

VYGVF Voyager Digital
$13.31 /

+0.205 (+1.56%)

Hot Stocks
Ford announces launch of VIIZR Software as a Service tool » 10:13
12/07/21
12/07
10:13
12/07/21
10:13
F

Ford

$19.63 /

+0.4 (+2.08%)

, CRM

Salesforce

$266.74 /

+8.01 (+3.10%)

Ford (F) announced its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
F Ford
$19.63 /

+0.4 (+2.08%)

CRM Salesforce
$266.74 /

+8.01 (+3.10%)

F Ford
$19.63 /

+0.4 (+2.08%)

12/06/21 Wedbush
Wedbush initiates Rivian Automotive with an Outperform, $130 price target
12/02/21 Wolfe Research
Wolfe Research downgrades Ford to Peer Perform after rally, now prefers GM
12/02/21 Citi
Citi electric vehicle pickup survey yields surprising, encouraging results
12/02/21 Wolfe Research
Ford downgraded to Peer Perform from Outperform at Wolfe Research
CRM Salesforce
$266.74 /

+8.01 (+3.10%)

12/02/21 Needham
Veeva price target lowered to $327 from $385 at Needham
12/01/21 Jefferies
Salesforce promotion of Taylor to co-CEO a positive, says Jefferies
12/01/21 Morgan Stanley
Salesforce Q3 'likely fell short' of expectations, says Morgan Stanley
12/01/21 Truist
Salesforce price target raised to $330 from $315 at Truist
F Ford
$19.63 /

+0.4 (+2.08%)

CRM Salesforce
$266.74 /

+8.01 (+3.10%)

F Ford
$19.63 /

+0.4 (+2.08%)

CRM Salesforce
$266.74 /

+8.01 (+3.10%)

F Ford
$19.63 /

+0.4 (+2.08%)

CRM Salesforce
$266.74 /

+8.01 (+3.10%)

F Ford
$19.63 /

+0.4 (+2.08%)

CRM Salesforce
$266.74 /

+8.01 (+3.10%)

Periodicals
Constellation Brands to construct brewery in Southeastern Mexico, WSJ reports » 10:12
12/07/21
12/07
10:12
12/07/21
10:12
STZ

Constellation Brands

$232.08 /

+1.37 (+0.59%)

, STZ.B

Constellation Brands; also tag STZ

$231.92 /

+17.61 (+8.22%)

Constellation Brands has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

STZ.B Constellation Brands; also tag STZ
$231.92 /

+17.61 (+8.22%)

STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

11/23/21 Morgan Stanley
Full Monster-Constellation combo 'less plausible' than JV, says Morgan Stanley
11/23/21 Citi
Citi 'highly skeptical' Coke would abandon relationship with Monster
11/22/21 Stifel
Monster-Constellation JV makes sense, merger 'less so,' says Stifel
11/01/21 Cantor Fitzgerald
Tilray downgraded to Neutral from Overweight at Cantor Fitzgerald
STZ.B Constellation Brands; also tag STZ
$231.92 /

+17.61 (+8.22%)

STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

STZ.B Constellation Brands; also tag STZ
$231.92 /

+17.61 (+8.22%)

STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

STZ.B Constellation Brands; also tag STZ
$231.92 /

+17.61 (+8.22%)

STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

STZ.B Constellation Brands; also tag STZ
$231.92 /

+17.61 (+8.22%)

STZ Constellation Brands
$232.08 /

+1.37 (+0.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.